Myriad Genetics Inc (MYGN) is a Healthcare · Diagnostics & Research company listed on NASDAQ. Price $4.05 (-2.17%), Market cap $0.34B, 52-week low–high $3.58 ~ $8.18.
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company of
Financial statements, price targets, institutional (13F) holdings and related news for Myriad Genetics Inc are updated in real time on BlackAll Trade.
Myriad Genetics Inc trades at $4.05 (-2.17%). Real-time quotes and charts are available on BlackAll Trade.
Myriad Genetics Inc has a market cap of about $0.34B.
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomic